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There is appreciable utilisation of antihistamines (H1) in European countries, either pre-
scribed by physician and purchased by patients for self-medication. Terfenadine and aste-
mizole underwent regulatory restrictions in ’90 because of their cardiac toxicity, but only
scarce clinical data are available on other antihistamines.
Aim
To investigate the pro-arrhythmic potential of antihistamines by combining safety reports of
the FDA Adverse Event Reporting System (FAERS) with drug utilization data from 13 Euro-
pean Countries.
Methods
We identified signals of antihistamine arrhythmogenic potential by analyzing FAERS data-
base for all cases of Torsades de Pointes (TdP), QT abnormalities (QTabn), ventricular ar-
rhythmia (VA) and sudden cardiac death/cardiac arrest (SCD/CA). Number of cases3
and disproportionality were used to define alert signals: TdP and QTabn identified stronger
signals, whereas SCD/CA identified weaker signals. Drug utilization data from 2005 to 2010
were collected from administrative databases through health authorities and insurance.
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Results
Antihistamines were reported in 109 cases of TdP/QT prolongation, 278 VA and 610 SCD/
CA. Five agents resulted in stronger signals (cetirizine, desloratadine, diphenhydramine,
fexofenadine, loratadine) and 6 in weaker signals (alimemazine, carbinoxamine, cyclizine,
cyproeptadine, dexchlorpheniramine and doxylamine). Exposure to antihistamines with
stronger signal was markedly different across European countries and was at least 40% in
each Country. Cetirizine was>29 Defined Daily Doses per 1000 inhabitants per day (DID)
in Norway, desloratadine>11 DID in France and loratadine>9 DID in Sweden and Croatia.
Drugs with weaker signals accounted for no more than 10% (in Sweden) and in most Euro-
pean countries their use was negligible.
Conclusions
Some second-generation antihistamines are associated with signal of torsadogenicity and
largely used in most European countries. Although confirmation by analytical studies is re-
quired, regulators and clinicians should consider risk-minimisation activities. Also antihista-
mines without signal but with peculiar use in a few Countries (e.g., levocetirizine) or with
increasing consumption (e.g., rupatadine) deserve careful surveillance.
Introduction
There is appreciable utilisation of antihistamines in European countries principally for the
treatment of allergies. Their main therapeutic effects are mediated by their activity on H1 re-
ceptors in immunoregulating cells, CNS, and smooth muscle. [1].
Their pharmacological profile can be grouped into either first-generation antihistamines,
e.g., diphenhydramine, and second-generation, e.g., cetirizine and loratadine. First-generation
agents readily reach the CNS, have high affinity for central H1 receptors and are mainly used in
the treatment of disorders related to the vomiting centre (motion sickness, post-operative or
drug-induced nausea and vomiting, vertigo, etc.) and for sedation (insomnia and anaesthesia).
Second-generation antihistamines only partially cross the blood brain barrier and are preferred
in allergic disorders (urticaria, conjunctivitis, rhinitis and hay fever) because of the lack of cen-
tral side effects [2]. Many administration routes are available for prescribing or self purchasing.
Pharmacological properties, indications, route of administration and formulations strongly in-
fluence the safety of use of antihistamines.
Drowsiness is the most frequent consequence of the oldest agents, whereas second-
generation antihistamines were developed to minimise this effect [1]: only high doses or pre-
disposing factors can impair patients’alertness. Antagonism of muscarinic, serotoninergic and
alpha-adrenergic transmission are responsible for other central and peripheral effects includ-
ing, for instance, blurred vision, urinary retention, constipation, weight gain, and orthostatic
hypotension. These side-effects are also more frequent for the first- rather than for the second-
generation agents.
Cardiac toxicity is less frequent than the side-effects described above. However, it is poten-
tially more severe for patients, with no well defined differences between first and second-
generation antihistamines.
Because of the relatively low incidence, the arrhythmogenic risk has principally been evalu-
ated in preclinical models rather than in patients. In fact, astemizole and terfenadine
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represented probably the first examples of widely used drugs withdrawn or strongly restricted
in the label due to risk of QT prolongation. This regulatory measure was also based on the con-
temporary marketing approval of many second-generation agents perceived as safer for cardiac
risk (e.g., fexofenadine, represents the active metabolite of terfenadine, and was especially de-
veloped to avoid the interaction with cardiac potassium channels and relevant ventricular ar-
rhythmia). The accurate clinical evaluation on the arrhythmogenic potential has become
mandatory before marketing authorisation (i.e., Thorough QT study—TQT) since 2005. So far,
though, these studies have only been conducted for three agents, namely bilastine, levocetiri-
zine and rupatadine, and in all cases provided negative results [3–6].
Almost all other antihistamines have not been included among drugs with this risk (absence
from Arizona CERT list, crediblemeds.org). The only exception is diphenhydramine, which is
included in the third list (i.e., conditional risk of TdP: substantial evidence supports the conclu-
sion that these drugs prolong QT and have a risk of developing TdP, but only under certain
known conditions).
Summary of Product Characteristics of medicinal products containing antihistamines do
not highlight this possible risk, apart from the inclusion of “tachycardia” among rare adverse
events in the side effect paragraph. No mention of proarrhythmic risk in cautions was found.
Aim
To primarily investigate the pro-arrhythmic potential of antihistamines in practice, by combin-
ing the analysis of safety reports of the FDA Adverse Event Reporting System (FAERS) with
drug utilization data from 13 European Countries.
The analysis of spontaneous reporting data will identify antihistamines with alert signals for
arrhythmia. Drug utilization data among European Countries will estimate population expo-
sure to these drugs in order to map the level of pro-arrhythmic potential due to antihistamine
utilization. The secondary aim is to update physicians and regulators about possible differences
in the proarrhythmic potential of antihistamines.
Methods
Ethics Statement
All data analyses performed in this retrospective study are based on anonymized data, which
did not allow the identification of individual patients. The study dealt with two independent
data sources, namely (a) spontaneous reports, which are publicly available from the FAERS da-
tabase and (b) drug utilization data, which can be accessed by other researchers only upon re-
quest to relevant personnel. Therefore, submission to and approval by the Institutional Review
Board was waived.
Pharmacovigilance Data
The FDA Adverse Event Reporting System (FAERS) database contains over 4 million reports
of Adverse Drug Reactions (ADRs) of worldwide human drugs and biological products and of-
fers public access to raw data starting from 2004. By virtue of its large population coverage (in-
cluding all US reports and serious/unexpected reports from European Countries) and free
availability, FAERS is an attracting source to explore rare adverse drug reactions (such as ar-
rhythmias) and highly informative of the global pattern of arrhythmogenic events. [7–10].
In a recent study [9], we described the consensus process to define the arrhythmogenic po-
tential of drugs within the FP7 funded ARITMO project (www.aritmo-project.org). In line
with this approach, we decided to investigate the arrhythmogenic potential of antihistamines
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by collecting all cases reported in the 2004–2011 period on: torsades de pointes (TdP), QT ab-
normalities (both symptomatic and asymptomatic), ventricular arrhythmia and sudden cardiac
death/cardiac arrest (respectively VA and SCD/CA). In particular, we first analyzed cases of
TdP or QT abnormalities (TdP/QTabn) as they are strongly intertwined with a high degree of
drug-attributable risk, whereas we considered separately ventricular arrhythmia and cardiac
arrest/sudden cardiac death (as they are not necessarily correlated with each other, have a
lower degree of drug-attributable risk, but represent possible symptomatic consequences of se-
vere QT prolongation and can increase the sensitivity of the analysis).
The Reporting Odds Ratio (ROR) with 95% CI was calculated for each group of events; dis-
proportion was considered in case of 95% Confidence Interval (95CI) (one-tailed) lower
limit>1. In addition, concomitant drugs were taken into account in order to better character-
ize each single case. We checked for co-reporting of cardiovascular classes (digitalis: C01A;
Class I/III antiarrhythmics: C01B; diuretics: C03; beta blockers: C07; calcium channel blockers:
C08 and ACE inhibitors/ARBs: C09) and lists I and II of the AZCERT program (crediblemeds.
org). AZCERT program currently represents the most authoritative source of evidence on the
torsadogenic risk of drugs and it was, therefore, used as a reference to establish the notoriety of
the arrhythmogenic risk, in order to discuss the novelty of the signals.
In order to allow conjunction analyses with drug utilization data and provide a public health
perspective, antihistamines were classified based on pharmacovigilance data as follows.
• Stronger signals: at least 3 cases without concomitant proarrhythmic drugs and ROR lower
limit>1for TdP/QTabn.
• Weaker signals: at least 3 cases without concomitant proarrhythmic drugs (see above) and
ROR lower limit>1for VA or CA/SCD.
Drug Utilization Data
After identification of pharmacovigilance signals from FAERS, drug utilization data allowed us
to map the risk derived from exposure to antihistamines in European Countries [10]. In this
study, data were collected from administrative databases through health authorities and health
insurance personnel across Europe. Consistent and reliable data were obtained from 13 Euro-
pean Countries, which allowed adequate estimation of European population exposure since the
13 Countries have differences in geography and financing of healthcare: i.e. comprisedWestern
(Austria, France, Italy, Norway, Spain [Catalonia], Sweden, and the UK [England and Scot-
land]), as well as Central and Eastern (Croatia, Serbia, Slovenia, Estonia, Lithuania) European
Countries and regions. With only a few exceptions, administrative databases contained data on
reimbursed prescriptions in ambulatory care and covered the entire population (see also Raschi
et al. [10] for details of data characteristics in each specific Country).
Total dispensed data (ATC code: R06) were expressed as defined daily doses (DDD) per 1,000 in-
habitants per day (now referred to as DID) for the 2005–2009/2010 period. In the analyses, we con-
sidered a detectable use of at least 0.01 DID. The mean annual DID value was used to estimate the
actual population exposure over the period of interest and to distinguish antihistamine use on the
basis of pharmacovigilance signals. A time-trend analysis was also carried out, where appropriate.
Results
Pharmacovigilance Data
Overall, 27 antihistamines were reported in at least one case of the outcomes of interest. They
were found in 109 cases of TdP/QT abnormalities (the most specific case definition);
Use of Antihistamines in Europe and Potential Proarrhythmic Risk
PLOS ONE | DOI:10.1371/journal.pone.0119551 March 18, 2015 4 / 14
loratadine, cetirizine and diphenhydramine accounted for the highest number of cases (26)
and in particular loratadine and cetirizine were reported in 17 and 13 cases of TdP, respectively
(Table 1). Eight drugs resulted in a ROR significantly>1 for these outcomes, but only 5 were
reported in at least 3 cases without concomitant confounding factors/drugs: cetirizine, deslora-
tadine, diphenhydramine, fexofenadine, loratadine (Table 1). On the basis of our signal defini-
tion, these five drugs present stronger alert signals.
By considering also more sensitive outcomes, antihistamines were reported in 278 cases of
VA (Table 2) with the 60% represented by non-fatal ventricular tachycardia (non-fatVT),
whereas cases of CA/SCD were 610, covered for the 90% by CA reports (Table 3). Diphenhy-
dramine was largely the most reported agent in both outcomes, followed by cetirizine and lora-
tadine in VA series and loratadine, doxylamine, dexchlorfeniramine and fexofenadine in CA/
SCD list.
Almost all signals emerging from analysis of TdP/QT abnormalities were confirmed by
both groups of more sensitive outcomes (i.e., VA and SCD). The following additional drugs
showed signal for at least one outcome group: cyclizine and dexchlorpheniramine appeared as
a signal by considering the cases of VA, whereas alimemazine, carbinoxamine, cyproeptadine
and doxylamine appeared with the outcomes of CA or SCD (Table 4). These latter 6 drugs
could be included in a list of weaker signals.
Drug Utilization Data
Considerable heterogeneity was observed in antihistamine utilization across Europe: e.g., in
2009, this ranged from 0.9 DID in Lithuania to 8.7 in Estonia, 18.8 in Slovenia, 22.4 in Scotland,
37.4 in France and 59.9 in Norway (Fig. 1). However, there was an appreciable increase in anti-
histamine utilisation throughout the study period. This ranged from a 7% increase in Norway
Table 1. Disproportionality analysis for antihistamines with cases of QT prolongation/TdP.
Cases of TdP; QTs; QTa ROR CI lower CI upper Cases without concomitant AZCERT drugs or CV drugs
alimemazine 0; 2; 3 9.14 3.75 22.28 2
azelastine 0; 1, 0 na na na 1
cetirizine 13; 4; 9 3.36 2.28 4.96 18
desloratadine 0; 2, 5 3.20 1.52 6.74 5
dexchlorpheniramine 5; 5; 2 7.00 3.94 12.41 2
diphenhydramine 6; 4; 16 1.99 1.35 2.92 12
doxylamine 0; 0; 1 na na na 1
ebastine 0; 1, 0 na na na 1
epinastine 1; 0; 0 na na na 0
fexofenadine 2; 2; 8 4.03 2.28 7.13 5
ketotifen 0; 0; 4 2.87 1.07 7.69 2
levocetirizine 0; 0; 3 2.63 0.84 8.19 3
loratadine 17; 4; 5 4.79 3.25 7.07 8
meclozine 1; 0; 0 na na na 0
mepyramine 0; 0; 1 na na na 1
promethazine 2; 2; 5 0.91 3.39 1
rupatadine 1; 0; 4 347.30 93.24 1293.68 0
NOTES: in italic, not statistically signiﬁcant ROR; na = number of cases <3; TdP = Torsades de Pointes, QTs = symptomatic QT prolongation,
QTa = asymptomatic QT prolongation.
doi:10.1371/journal.pone.0119551.t001
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to 21% in Austria (2010 vs 2005). Serbia is an exception, with a peak in 2007 but a negligible
variation throughout the study period. Concerning the contribution of different supplying regi-
mens to the collected data, Serbia and Sweden showed very different situations. In Serbia, total
utilization including dispensed prescriptions of drugs not covered by the Health Insurance
Fund was appreciably higher than reimbursed utilisation (8.8 to 12.3 total vs. 2.0 to 3.2 reim-
bursed utilisation), whereas in Sweden, there was lower over the counter (OTC) use than reim-
bursed utilisation (10.1 to 11.6 OTC and 23.3 to 24.6 reimbursed).
Antihistamines with stronger signals represented a very different percentage of the total an-
tihistamine utilization in each Country, e.g. ranging from 43% in Spain (Catalonia) to 97% in
Croatia (Fig. 2). Among these, cetirizine was>29 DID in Norway, desloratadine>11 DID in
France and loratadine>9 DID in Sweden and Croatia (Fig. 3). Drugs with weak signals ac-
counted for no more than 10% (in Sweden) and in most Countries their use was negligible.
Discussion
This study attempts, for the first time, to combine analysis of drug utilisation and pharmacov-
igilance data to interpret signals of arrhythmogenicity related to antihistamines. Our findings
showed signals of arrhythmogenicity especially for second-generation agents for which no pre-
vious pharmacovigilance data were published: cetirizine, desloratadine, fexofenadine, lorata-
dine. Among old agents, only diphenhydramine fulfilled criteria for signal generation. These
Table 2. Disproportionality analysis for antihistamines with cases of ventricular arrhythmia.
cases of VF; fatVT; non-fatVT ROR CI lower CI upper cases without concomitant AZCERT or CV drugs
alimemazine 0;4;0 1.83 0.68 4.95 1
azelastine 1;0;2 1.48 0.47 4.65 2
brompheniramine 0;1;1 0.82 0.20 3.30 1
buclizine 0;0;1 na na na 0
carbinoxamine 0;1;2 2.47 0.78 7.83 3
cetirizine 7;3;24 1.11 0.79 1.56 20
chlorphenamine 0;0;5 1.00 0.41 2.41 5
cyclizine 1;0;8 22.54 10.63 47.77 4
desloratadine 1;1;26 3.35 2.29 4.89 24
dexbrompheniramine 0;1;1 14.02 3.07 63.99 2
dexchlorpheniramine 0;13;13 3.94 2.65 5.85 19
diphenhydramine 6;33;53 1.81 1.47 2.22 50
doxylamine 0;3;1 1.04 0.39 2.80 2
ebastine 0;0;1 na na na 1
epinastine 1;0;1 1.77 0.44 7.22 2
fexofenadine 1;3;19 1.97 1.30 2.99 15
ketotifen 0;0;1 na na na 1
levocetirizine 0;1;4 1.11 0.46 2.69 4
loratadine 5;3;24 1.49 1.05 2.12 26
meclozine 0;0;1 na na na 0
pheniramine 1;0;0 na na na 0
thiethylperazine 0;1;1 1.89 0.26 13.81 2
triprolidine 0;0;1 na na na 1
NOTES: in italic, not statistically signiﬁcant ROR; na = number of cases <3;VF = ventricular ﬁbrillation; fatVT = fatal or life-threatening ventricular
ﬁbrillation; non-fatVT = other VT cases.
doi:10.1371/journal.pone.0119551.t002
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five drugs covered more than 40% of total consumption of antihistamines in each European
Country, ranging from 43% in Spain to 97% in Croatia. On the other hand, utilisation of drugs
with weaker signal (cyclizine, dexchlorpheniramine, alimemazine, carbinoxamine, cyproepta-
dine and doxylamine) was negligible, except for Sweden, Norway and France where it ranged
from 6 to 10% of total antihistamine utilisation.
Concerning pharmacovigilance results, it should be reminded that generated signals
represent input to systematically review all available case-reports in the literature [11] and to
perform formal analytical studies (i.e., case-control studies) to confirm or refuse actual causal-
effect relationship in order to better substantiate possible regulatory and clinical decisions; on
the other hand, signals can per se stimulate attention of regulators and in some cases justify reg-
ulatory interventions before confirmation of safety concerns, especially when therapeutic alter-
natives with solid evidence of safety are available on the market. In this context, Countries with
overall high use of antihistamines with unexpected signals (i.e., Croatia, Norway, England and
Sweden) should probably take measures to limit population exposure to these drugs. Also the
contribution to total exposure from OTC use should be taken into account by regulators, be-
cause of difficult patient monitoring by physicians. As a matter of fact, differences seen between
Serbia and Sweden may be due to differences in patient co-payments (high vs. low OTC
consumption).
When findings on antihistamines are compared with those in other therapeutic areas, some
general issues should be first considered: the absolute number of cases of arrhythmia is low (es-
pecially against antipsychotics and antibiotics [10;12]); patients exposed to antihistamines have
probably less risk factors for arrhythmia (most prevalent indications for antihistamine use are
mild and not related to cardiovascular comorbidities); on the other hand, strict monitoring of
patients treated with antihistamines is rare and this may contribute to the lack of identification
Table 3. Disproportionality analysis for antihistamines with cases of cardiac arrest (CA) or sudden cardiac death (SCD).
cases of CA; SCD ROR CI lower CI upper cases without concomitant AZCERT or CV drugs
alimemazine 7;1 2.77 1.36 5.63 4
azelastine 4;1 1.84 0.75 4.49 4
brompheniramine 3;3 1.85 0.82 4.18 6
carbinoxamine 8;4 8.13 4.42 14.95 12
cetirizine 14;6 0.48 0.31 0.74 15
chlorcyclizine 0;1 na na na 0
chlorphenamine 3;4 1.03 0.49 2.18 6
cyproheptadine 15;0 8.49 4.92 14.66 1
desloratadine 10;3 1.11 0.64 1.93 11
dexchlorpheniramine 27;8 3.97 2.82 5.60 21
dimetindene 0;1 na na na 0
diphenhydramine 366;21 6.13 5.52 6.82 215
doxylamine 34;2 7.83 5.51 11.12 18
ebastine 2;0 2.78 0.67 11.55 2
fexofenadine 24;10 2.17 1.54 3.06 9
levocetirizine 5;1 0.98 0.44 2.21 6
loratadine 39;4 1.48 1.09 2.01 17
meclozine 3;0 1.13 0.36 3.54 2
thiethylperazine 0;1 na na na 1
NOTES: in italic, not statistically signiﬁcant ROR; na = number of cases <3
doi:10.1371/journal.pone.0119551.t003
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of non-severe events (e.g., asymptomatic QT abnormalities). Therefore, reports of arrhythmia
by antihistamines are more likely to have a higher drug-attributable component: antihista-
mines induced arrhythmia less frequently than other drugs, probably because exposed patients
had no additional risk factors rather because intrinsically lower risk.
Reasons listed above can potentially explain the lack of antihistamines in the AZCERT list.
In fact, only diphenhydramine is included in the III list (i.e., weak evidence of risk, which may
be clinically relevant only in susceptible patients). All other antihistamines, therefore, generat-
ed unknown signals and each of them should be specifically discussed. With regard to deslora-
tadine, a recent prescription event monitoring (PEM) [13] showed no evidence for arrhythmia
when used in general practice in England. On fexofenadine, the case of TdP reported in 1999
by Pinto et al. [14] remained the only one in the literature attributed to this agent and all arti-
cles published later excluded a drug-attributable risk of arrhythmia [15–17]. On the other
hand, it should be acknowledged that fexofenadine monotherapy (i.e. without any concomitant





















alimemazine Y1 Y Y N Y Y Weaker
azelastine N N Y N Y N
brompheniramine N na N na Y N
buclizine na na N na Na na
carbinoxamine na na Y N Y Y Weaker
cetirizine Y Y Y N Y N Stronger
chlorphenamine Na na Y N Y N
cyclizine Na na Y Y Na na Weaker
cyproheptadine Na na na na Y Y Weaker
desloratadine Y Y Y Y Y N Stronger
dexbrompheniramine Na na N na Na na
dexchlorpheniramine Y1 Y Y Y Y Y Weaker2
diphenhydramine Y Y Y Y Y Y III Stronger
doxylamine N na Y N Y Y Weaker
ebastine N na N na N na
epinastine N na N na Na na
fexofenadine Y Y Y Y Y Y Stronger
ketotifen Y1 Y N na Na na borderline2
levocetirizine Y N Y N Y N
loratadine Y Y Y Y Y Y Stronger
meclozine N na N na Y N
mepyramine N na na na Na na
pheniramine Na na N na Na na
promethazine Y1 N na na Na na
rupatadine Y1 Y na na Na na borderline2
thiethylperazine na na N na N na
triprolidine na na N na Na na
1less than 3 cases without AZCERT drugs or CV drugs; QTs = symptomatic QT prolongation, QTa = asymptomatic QT prolongation.
2 stronger signal was not reached only due to lack of 3 cases without AZCERT drugs or CV drugs
doi:10.1371/journal.pone.0119551.t004
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drug) was reported in a not negligible percentage of cases of arrhythmia recorded in FDA Ad-
verse Event Reporting System: 5 out of 12 cases of TdP/QTabn, 15 out of 24 VA cases and 7
out of 34 of CA/SCD cases. As for loratadine and cetirizine, some published papers reported
cases of arrhythmia in patients taking poly-pharmacy or overdose [18–22], but the specific
contribution of antihistamines in the adverse events was not finally identified. The debate is
still ongoing, but so far large observational analyses [23] and preclinical studies [24–26] failed
to demonstrate a role of these two agents in cardiac repolarisation impairments.
In the risk—benefit assessment of each medicine, also indication and setting of use should
be taken into account. In particular, some antihistamines are used especially as antinausea/
antiemesis drugs, e.g., promethazine and cyclizine. For these drugs, the peculiar clinical setting,
i.e., palliative care in patients with cancer or critically-ill patients, may facilitate the occurrence
of TdP and a comparison with alternative drugs used in the same conditions, e.g., ondansetron,
could better clarify their possible proarrhythmic risk.
Some antihistamines, although not showing clear signals in current analysis, ask for con-
tinuing surveillance. Agents largely used only in a few countries also need further investigation
on their proarrhythmic risk in the national database. In particular, the very high use of levoce-
tirizine in France (53% of the total defined daily doses of antihistamines) and the fact that most
FAERS cases of arrhythmia reporting levocetirizine are from France (8/14) suggests the need to
specifically analyse the French spontaneous report databases-. Differences in safety profile, and
in signal generation, between enantiomer and racemic mixture (i.e., levocetirizine and cetiri-
zine) should not surprise because of possible differences in doses, metabolism and stereoselec-
tive targets [27].
Surveillance is also recommended for antihistamines, which met some of the considered cri-
teria, but did not reach the full definition of signal. This is especially the case of rupatadine,
which was marketed in 2008 and shows steadily increasing use: e.g. Spain and Italy showed a
Fig 1. Cross-National Comparison: time trend. AUT: Austria; CRO: Croatia; EST: Estonia; FRA: France; IT: Italy; LIT: Lithuania; NOR: Norway; SPA:
Spain (Catalonia); SCO: Scotland; SER: Serbia; SLO: Slovenia; SWE: Sweden. ENG: 2008–2010; EST: 2006–2010; FRA: 2005–2008; ITA: 2006–2010;
SPA: 2006–2010; SWE: 2007–2010. Data from Norway and Sweden include also hospital data. Data from Sweden also includes OTC data.
doi:10.1371/journal.pone.0119551.g001
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consumption of 0.71 and 0.38 defined daily doses in the observed time-window. On the basis
of our data, rupatadine was reported in 1 case of TdP and 4 of asymptomatic QT prolongation,
reporting odds ratio resulted statistically significant, but in most cases known proarrhythmic
drugs were co-prescribed. Information of its proarrhythmic profile includes also a Thorough
QT study [6], which provided negative results, and, by contrast, a recent warning from the Ital-
ian Medicine Agency on some spontaneous reports of cardiac rhythm impairment [http://
www.agenziafarmaco.gov.it/sites/default/files/Rupatadina_29.5.2013.pdf].
High consumption of antihistamines in Norway and Sweden found in our study is in line
with a previous drug utilisation survey [28], which proposed a higher data quality as potential
reason for this finding. In this regard, each Country should check for data quality before defini-
tively deciding regulatory strategies (e.g., Lithuania should verify its very low consumption of
antihistamines, which may be due to issues of reimbursement restrictions similar to the situa-
tion for proton pump inhibitors and statins versus Western European countries [29]).
Strengths and Limitations
Intrinsic limitations of pharmacovigilance analyses are well known and should be briefly ac-
knowledged here: [11] while modern adverse event reporting into FAERS suggests that so-
called Weber effect and stimulated reporting do not significantly and systematically affect
spontaneous reporting analyses [30;31], the issue of under-reporting together with the lack of
data on population exposure actually do not allow calculation of incidence rate of ADRs from
spontaneous reporting systems, even when they are as large as FDA Adverse Event Reporting
Fig 2. Antihistamine utilisation on the basis of pharmacovigilance signals.
doi:10.1371/journal.pone.0119551.g002
Use of Antihistamines in Europe and Potential Proarrhythmic Risk
PLOS ONE | DOI:10.1371/journal.pone.0119551 March 18, 2015 10 / 14
System. Therefore, signal detection asks per se for confirmation through additional analytical
studies or systematic review of clinical data with relevant meta-analyses, especially for rare
events. Our specific methodology attempted to characterize statistically significant signals
(i.e., disproportionality formally obtained) considering additional qualitative information (i.e.,
number of cases without confounders) and the clinical relevance of the event of interest (i.e.,
TdP, which carries stronger drug-related component as compared to ventricular arrhythmia)
in order to prioritize signals for potential regulatory consideration (e.g., according to the extent
of local drug use).
Also drug utilisation data suffer from well-known limitations: discrepancy between supplied
and actually administered drugs is common to all drug utilisation data collections. Moreover,
in some countries, only reimbursed prescriptions can be collected, and reimbursement systems
are heterogeneous across Europe. Also when Countries are able to collect sales data, hospital
data could be missing, although for some drug classes (e.g., antihistamines) they represent only
a low percentage of the total consumption. Despite limitations, the DDD system is a recognized
tool for standardizing doses in drug utilization research and is currently recommended by the
WHO for international drug utilization studies [32].
Although also serious and rare European reports are submitted to the FDA, our data may be
affected by specific drug marketing penetration (e.g., drugs only marketed in Europe). In addi-
tion, the characterization of signals is dynamic so that a given antihistamine may change
strength of signal (i.e., strong vs weak) depending on the availability of new pharmacovigilance
data over time. This is particularly important for drugs classified as weak or borderline signals,
Fig 3. Utilisation of different antihistamines with stronger signals.
doi:10.1371/journal.pone.0119551.g003
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which therefore require monitoring in the next years to fully appreciate their actual post-
marketing safety profile.
This study attempted to overcome the lack of information on exposed population in sponta-
neous reporting sources, by linking FAERS findings with drug consumption. It should be kept
in mind that results derived from a combination of both data sources must be interpreted very
cautiously, because information are obtained from separate databases, which are affected by
different bias (see above). In addition, the link between drug utilization data and spontaneous
reports is not straightforward. In most of the cases, adverse events track the magnitude of utili-
zation, meaning that the volume of spontaneous reports largely mirror the prescribing trend.
As a matter of fact, it should be acknowledged that antihistamines with strong signal are also
largely and consistently used across Europe.
However, the aim of our study was to approach pharmacovigilance data (derived by the
clinical pharmacology perspective of single patients) in a population risk perspective and to
provide risk weighting at the population level. Although pharmacovigilance and drug utiliza-
tion data sources did not cover the same geographical area (only Europe for drug utilization
and theoretically all Countries for pharmacovigilance), we used these two dataset for different
purposes: (a) FAERS, the largest public pharmacovigilance database, to accurately classify and
characterize torsadogenic signals by antihistamines, and (b) European drug utilization data to
map the overall antihistamine use (i.e., estimate the European population exposure).
Conclusions
Combined analysis of pharmacovigilance and drug utilisation data can provide useful elements
for clinicians and regulators in terms of population perspectives of safety concerns of drugs.
Some antihistamines resulted in signals of torsadogenic risk and most of them are largely
used especially in some European Countries.
National Agencies should focus their attention on own peculiar uses of antihistamines and
define strategies to minimise proarrhythmic potential, also in the light of their multiple place
in therapy and the difficulty in monitoring their use by physicians because of the high frequen-
cy of self-medication. Educational initiatives focussed on recognition of patient susceptibility
and possible differences in the potential risk among single agents should be addressed.
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